Trial Profile
Phase II study of MK-8031 in patients with migraine
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2016 Status changed from planning to recruiting, according to Allergan media release.
- 09 Jul 2015 New trial record